Extracting and calibrating evidence of variant pathogenicity from population biobank data
Vineel BhatiD, Tian Yu, Lara Brown, Vikas Rao PejaveriD, Matthew S. LeboiD, Steven M. HarrisoniD, Christopher A. CassaiD
Abstract
Genomic medicine requires a robust evidence base of variant phenotypic impacts, which remains incomplete even in extensively studied monogenic disease genes. Here, we evaluated the broad potential of using population cohort data to identify evidence that can be used in variant assessment. Across 41 genes related to 18 clinically actionable monogenic phenotypes, we calculated variant-level odds ratios of disease enrichment using data from 469,803 UK Biobank participants. We found significant differences in odds ratio values between ClinVar-labeled pathogenic and benign variants in 11 phenotypes, spanning both common and rare disorders. To facilitate clinical translation, we calibrated the strength of evidence provided by variant-level odds ratios to align with American College of Medical Genetics and Genomics (ACMG/AMP) interpretation guidelines (PS4 criterion), and found that odds ratios may reach moderate, strong, or very strong evidence, varying by phenotype and gene. Overall, we found that 2.6% (N = 12,350) of participants harbor a rare VUS with at least moderate evidence of pathogenicity - an indication of potentially unrecognized disease risk. Finally, by incorporating computational and functional data alongside population-based odds ratios, we identified variants that met criteria for clinical reclassification. Notably, using this approach, we identified that 12.4% of rare VUS in LDLR seen in participants meet diagnostic criteria to be classified as likely pathogenic, demonstrating its potential to scale the reclassification of VUS. HighlightsO_LIWe identify rare coding variants that alter risk across 41 genes related to 18 actionable phenotypes. C_LIO_LIWe find enrichments of cases in variants of uncertain significance related to rare and common disorders. C_LIO_LIWe calibrate the strength of biobank population evidence for use in sequence variant interpretation. C_LIO_LIWe combine evidence to identify uncertain variants that can be reclassified as likely pathogenic. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 11
- FWCI
- 6.47
- Field percentile
- top 2%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Endophenotype Effect Sizes Provide Evidence Supporting Variant Pathogenicity in Monogenic Disease Susceptibility Genes
Jennifer L. Halford, Valerie N. Morrill, … Steven A. Lubitz·Nature CommunicationsPeer-reviewed·Aug 30, 2022
- Assessing the pathogenicity, penetrance and expressivity of putative disease-causing variants in a population setting
Caroline Fiona Wright, Ben West, … Michael N. Weedon·The American Journal of Human GeneticsPeer-reviewed·Jan 18, 2019
- A scalable approach to resolving variants of uncertain significance
Malvika Tejura, Y P Chen, … Lea M. Starita·bioRxiv·Feb 23, 2026
- Language models reveal evidence gaps in variants of uncertain significance
Weijiang Li, Vineel Bhat, … Christopher A. Cassa·medRxiv·Mar 2, 2026
- From Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World Evidence
Kelly M. Schiabor Barrett, Matthew J. Ferber, … Elizabeth T. Cirulli·medRxiv·Aug 12, 2025
- A framework for integrated clinical risk assessment using population sequencing data
James D. Fife, Tho Dinh Tran, … Christopher A. Cassa·medRxiv·Aug 12, 2021